SPY316.18+2.40 0.76%
DIA260.72+1.68 0.65%
IXIC10,492.50+148.61 1.44%

Oncolytics Biotech Doses First Patient In Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies In Metastatic Breast Cancer

Study will evaluate pelareorep's ability to synergistically combine with the checkpoint inhibitor therapy avelumab and improve outcomes in metastatic breast cancer Study aims to validate T cell clonality as a

Benzinga · -

Study will evaluate pelareorep's ability to synergistically combine with the checkpoint inhibitor therapy avelumab and improve outcomes in metastatic breast cancer
Study aims to validate T cell clonality as a biomarker of pelareorep response and enable advancement into a phase 3 registrational study
BRACELET-1 is being conducted under a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer

SAN DIEGO and CALGARY, Alberta, June 23, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC). The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business in the US and Canada as EMD Serono, and Pfizer Inc. (NYSE:PFE). Participants in the study receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with paclitaxel and Merck KGaA, Darmstadt, Germany and Pfizer's anti-PD-L1 checkpoint inhibitor, avelumab (Bavencio®).